The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization

[1]  Eike Nagel,et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[2]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[3]  P. Matthews,et al.  Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study , 2020, The Lancet Psychiatry.

[4]  Y. Tie,et al.  Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[5]  H. Nishiura,et al.  Clusters of Coronavirus Disease in Communities, Japan, January–April 2020 , 2020, Emerging infectious diseases.

[6]  David J Murphy,et al.  ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019 , 2020, Critical care medicine.

[7]  Bruce Y. Lee,et al.  The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. , 2020, Health affairs.

[8]  Robert J. Cerfolio,et al.  Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City , 2020, medRxiv.

[9]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[10]  Heshui Shi,et al.  Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study , 2020, Radiology.

[11]  Center for Biologics Evaluation and Research , 2020, Definitions.

[12]  J. Singleton,et al.  Vaccination Coverage by Age 24 Months Among Children Born in 2015 and 2016 — National Immunization Survey-Child, United States, 2016–2018 , 2019, MMWR. Morbidity and mortality weekly report.

[13]  Louis P Garrison,et al.  Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[15]  Tara Kirk Sell,et al.  Mass vaccination for the 2009 H1N1 pandemic: approaches, challenges, and recommendations. , 2010, Biosecurity and bioterrorism : biodefense strategy, practice, and science.